Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ATP1A1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ATP1A1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATP1A1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATP1A1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ATP1A1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATP1A1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATP1A1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ATP1A1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ATP1A1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ATP1A1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ATP1A1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00300042 | Colorectum | MSS | cellular monovalent inorganic cation homeostasis | 31/3467 | 103/18723 | 2.94e-03 | 2.27e-02 | 31 |
GO:0086064 | Colorectum | MSS | cell communication by electrical coupling involved in cardiac conduction | 11/3467 | 25/18723 | 2.96e-03 | 2.28e-02 | 11 |
GO:0070252 | Colorectum | MSS | actin-mediated cell contraction | 29/3467 | 97/18723 | 4.38e-03 | 3.10e-02 | 29 |
GO:0086003 | Colorectum | MSS | cardiac muscle cell contraction | 23/3467 | 73/18723 | 5.22e-03 | 3.57e-02 | 23 |
GO:00030121 | Colorectum | MSS | muscle system process | 105/3467 | 452/18723 | 6.39e-03 | 4.26e-02 | 105 |
GO:19026003 | Colorectum | MSI-H | proton transmembrane transport | 29/1319 | 157/18723 | 1.49e-06 | 9.75e-05 | 29 |
GO:00329703 | Colorectum | MSI-H | regulation of actin filament-based process | 49/1319 | 397/18723 | 8.99e-05 | 2.90e-03 | 49 |
GO:00860651 | Colorectum | MSI-H | cell communication involved in cardiac conduction | 12/1319 | 58/18723 | 6.11e-04 | 1.20e-02 | 12 |
GO:0006937 | Colorectum | MSI-H | regulation of muscle contraction | 24/1319 | 169/18723 | 7.87e-04 | 1.46e-02 | 24 |
GO:00551171 | Colorectum | MSI-H | regulation of cardiac muscle contraction | 14/1319 | 77/18723 | 8.78e-04 | 1.57e-02 | 14 |
GO:00485453 | Colorectum | MSI-H | response to steroid hormone | 40/1319 | 339/18723 | 9.37e-04 | 1.64e-02 | 40 |
GO:00020283 | Colorectum | MSI-H | regulation of sodium ion transport | 15/1319 | 90/18723 | 1.48e-03 | 2.23e-02 | 15 |
GO:00902573 | Colorectum | MSI-H | regulation of muscle system process | 31/1319 | 252/18723 | 1.74e-03 | 2.52e-02 | 31 |
GO:00860043 | Colorectum | MSI-H | regulation of cardiac muscle cell contraction | 8/1319 | 34/18723 | 2.07e-03 | 2.86e-02 | 8 |
GO:00860011 | Colorectum | MSI-H | cardiac muscle cell action potential | 13/1319 | 76/18723 | 2.35e-03 | 3.12e-02 | 13 |
GO:0006942 | Colorectum | MSI-H | regulation of striated muscle contraction | 15/1319 | 95/18723 | 2.56e-03 | 3.38e-02 | 15 |
GO:0061337 | Colorectum | MSI-H | cardiac conduction | 15/1319 | 98/18723 | 3.48e-03 | 4.18e-02 | 15 |
GO:00329704 | Colorectum | FAP | regulation of actin filament-based process | 105/2622 | 397/18723 | 3.15e-11 | 1.38e-08 | 105 |
GO:00300483 | Colorectum | FAP | actin filament-based movement | 44/2622 | 127/18723 | 3.48e-09 | 5.93e-07 | 44 |
GO:00713833 | Colorectum | FAP | cellular response to steroid hormone stimulus | 59/2622 | 204/18723 | 2.12e-08 | 2.06e-06 | 59 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0426016 | Breast | Precancer | Cardiac muscle contraction | 22/684 | 87/8465 | 9.72e-07 | 1.62e-05 | 1.24e-05 | 22 |
hsa0496110 | Breast | Precancer | Endocrine and other factor-regulated calcium reabsorption | 11/684 | 53/8465 | 2.92e-03 | 1.81e-02 | 1.39e-02 | 11 |
hsa0497114 | Breast | Precancer | Gastric acid secretion | 13/684 | 76/8465 | 7.35e-03 | 4.07e-02 | 3.12e-02 | 13 |
hsa0426017 | Breast | Precancer | Cardiac muscle contraction | 22/684 | 87/8465 | 9.72e-07 | 1.62e-05 | 1.24e-05 | 22 |
hsa0496111 | Breast | Precancer | Endocrine and other factor-regulated calcium reabsorption | 11/684 | 53/8465 | 2.92e-03 | 1.81e-02 | 1.39e-02 | 11 |
hsa0497115 | Breast | Precancer | Gastric acid secretion | 13/684 | 76/8465 | 7.35e-03 | 4.07e-02 | 3.12e-02 | 13 |
hsa0426022 | Breast | IDC | Cardiac muscle contraction | 23/867 | 87/8465 | 1.39e-05 | 1.61e-04 | 1.21e-04 | 23 |
hsa0491916 | Breast | IDC | Thyroid hormone signaling pathway | 23/867 | 121/8465 | 2.45e-03 | 1.69e-02 | 1.27e-02 | 23 |
hsa0497122 | Breast | IDC | Gastric acid secretion | 16/867 | 76/8465 | 3.80e-03 | 2.33e-02 | 1.74e-02 | 16 |
hsa049704 | Breast | IDC | Salivary secretion | 18/867 | 93/8465 | 5.69e-03 | 3.13e-02 | 2.34e-02 | 18 |
hsa0496121 | Breast | IDC | Endocrine and other factor-regulated calcium reabsorption | 12/867 | 53/8465 | 6.29e-03 | 3.30e-02 | 2.47e-02 | 12 |
hsa0497812 | Breast | IDC | Mineral absorption | 13/867 | 60/8465 | 6.73e-03 | 3.42e-02 | 2.56e-02 | 13 |
hsa0426032 | Breast | IDC | Cardiac muscle contraction | 23/867 | 87/8465 | 1.39e-05 | 1.61e-04 | 1.21e-04 | 23 |
hsa0491917 | Breast | IDC | Thyroid hormone signaling pathway | 23/867 | 121/8465 | 2.45e-03 | 1.69e-02 | 1.27e-02 | 23 |
hsa0497132 | Breast | IDC | Gastric acid secretion | 16/867 | 76/8465 | 3.80e-03 | 2.33e-02 | 1.74e-02 | 16 |
hsa0497011 | Breast | IDC | Salivary secretion | 18/867 | 93/8465 | 5.69e-03 | 3.13e-02 | 2.34e-02 | 18 |
hsa0496131 | Breast | IDC | Endocrine and other factor-regulated calcium reabsorption | 12/867 | 53/8465 | 6.29e-03 | 3.30e-02 | 2.47e-02 | 12 |
hsa0497813 | Breast | IDC | Mineral absorption | 13/867 | 60/8465 | 6.73e-03 | 3.42e-02 | 2.56e-02 | 13 |
hsa0491918 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa0497116 | Cervix | CC | Gastric acid secretion | 20/1267 | 76/8465 | 6.93e-03 | 2.27e-02 | 1.34e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP1A1 | SNV | Missense_Mutation | novel | c.784G>T | p.Gly262Trp | p.G262W | P05023 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
ATP1A1 | SNV | Missense_Mutation | | c.208G>C | p.Glu70Gln | p.E70Q | P05023 | protein_coding | tolerated(0.09) | benign(0.258) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ATP1A1 | SNV | Missense_Mutation | novel | c.1522A>C | p.Lys508Gln | p.K508Q | P05023 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP1A1 | SNV | Missense_Mutation | | c.1553N>A | p.Cys518Tyr | p.C518Y | P05023 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
ATP1A1 | SNV | Missense_Mutation | novel | c.1534N>A | p.Glu512Lys | p.E512K | P05023 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP1A1 | SNV | Missense_Mutation | | c.2450T>C | p.Val817Ala | p.V817A | P05023 | protein_coding | tolerated(0.06) | possibly_damaging(0.466) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ATP1A1 | SNV | Missense_Mutation | | c.2175G>T | p.Leu725Phe | p.L725F | P05023 | protein_coding | deleterious(0.01) | possibly_damaging(0.747) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
ATP1A1 | SNV | Missense_Mutation | | c.1223G>A | p.Gly408Asp | p.G408D | P05023 | protein_coding | tolerated(0.06) | benign(0.363) | TCGA-E2-A14Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
ATP1A1 | insertion | In_Frame_Ins | novel | c.117_118insCTCACCCTTTGCCTGTCAGTTGTTCAGCGTGTAACAGTTCCCTGC | p.Val39_Ser40insLeuThrLeuCysLeuSerValValGlnArgValThrValProCys | p.V39_S40insLTLCLSVVQRVTVPC | P05023 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ATP1A1 | insertion | Frame_Shift_Ins | novel | c.2365_2366insTACCCCAGAAAAGGGAAAA | p.Pro789LeufsTer29 | p.P789Lfs*29 | P05023 | protein_coding | | | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
476 | ATP1A1 | ION CHANNEL, DRUGGABLE GENOME, TRANSPORTER, ENZYME, CLINICALLY ACTIONABLE | | ISTAROXIME | ISTAROXIME | |
476 | ATP1A1 | ION CHANNEL, DRUGGABLE GENOME, TRANSPORTER, ENZYME, CLINICALLY ACTIONABLE | | Chloroprocaine | CHLOROPROCAINE | |
476 | ATP1A1 | ION CHANNEL, DRUGGABLE GENOME, TRANSPORTER, ENZYME, CLINICALLY ACTIONABLE | | ACETYLDIGITOXIN | ACETYLDIGITOXIN | |
476 | ATP1A1 | ION CHANNEL, DRUGGABLE GENOME, TRANSPORTER, ENZYME, CLINICALLY ACTIONABLE | | ALMITRINE | ALMITRINE | |
476 | ATP1A1 | ION CHANNEL, DRUGGABLE GENOME, TRANSPORTER, ENZYME, CLINICALLY ACTIONABLE | | Deslanoside | DESLANOSIDE | |
476 | ATP1A1 | ION CHANNEL, DRUGGABLE GENOME, TRANSPORTER, ENZYME, CLINICALLY ACTIONABLE | | DIGOXIN | DIGOXIN | |
476 | ATP1A1 | ION CHANNEL, DRUGGABLE GENOME, TRANSPORTER, ENZYME, CLINICALLY ACTIONABLE | | DESLANOSIDE | DESLANOSIDE | |
476 | ATP1A1 | ION CHANNEL, DRUGGABLE GENOME, TRANSPORTER, ENZYME, CLINICALLY ACTIONABLE | | DESLANOSIDE | DESLANOSIDE | |
476 | ATP1A1 | ION CHANNEL, DRUGGABLE GENOME, TRANSPORTER, ENZYME, CLINICALLY ACTIONABLE | | BEPRIDIL | BEPRIDIL | |
476 | ATP1A1 | ION CHANNEL, DRUGGABLE GENOME, TRANSPORTER, ENZYME, CLINICALLY ACTIONABLE | | DIGITOXIN | DIGITOXIN | |